Why is Natraj Proteins Ltd falling/rising?

Recent Price Movement and Market Behaviour

On 02-Mar, the stock opened with a gap down of 2.13%, signalling immediate bearish sentiment among investors. Throughout the trading session, the share price exhibited high volatility, with an intraday range of ₹3.6 and a low of ₹28.6, marking a 13.07% decline from previous levels. The weighted average price indicated that a larger volume of shares traded closer to the day’s low, underscoring selling pressure. This price action was accompanied by a notable drop in investor participation, with delivery volumes on 27 Feb falling by 65.59% compared to the five-day average, suggesting waning confidence among shareholders.

Furthermore, the stock has been on a downward trajectory for two consecutive days, losing 9.3% over this period. It has also underperformed its sector by 6.52% on the day, highlighting relative weakness. Technical indicators reinforce this bearish outlook, as Natraj Proteins is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.

Long-Term Performance and Benchmark Comparison

Over the past year, Natraj Proteins has delivered a disappointing return of -27.58%, starkly contrasting with the Sensex’s positive 9.62% gain during the same period. This underperformance extends over longer horizons as well, with the stock declining 37.33% over three years while the Sensex surged 36.21%. Even over five years, the stock’s modest 6.89% gain pales in comparison to the benchmark’s 59.53% rise. Such consistent lagging performance against major indices and sector peers has likely contributed to investor scepticism and selling pressure.

Fundamental Analysis: Strengths and Weaknesses

Despite the recent share price decline, Natraj Proteins reported encouraging quarterly results in December 2025, marking a turnaround after two consecutive negative quarters. The company posted its highest quarterly PBDIT of ₹3.54 crores and achieved an operating profit margin of 12.30%, alongside a PBT less other income of ₹2.86 crores. These figures indicate operational improvements and a potential recovery in profitability.

Valuation metrics also suggest the stock is attractively priced relative to its capital employed, with an enterprise value to capital employed ratio of 0.6 and a return on capital employed (ROCE) of 1. The company’s PEG ratio stands at a low 0.1, reflecting that profits have surged by 175% over the past year despite the stock’s negative price performance. This disparity may indicate that the market has yet to fully price in the company’s improving earnings trajectory.

However, these positives are overshadowed by weak long-term fundamentals. The company’s net sales have contracted at a compound annual growth rate (CAGR) of -5.06% over the last five years, signalling declining top-line momentum. Additionally, the average return on equity (ROE) is a modest 6.97%, reflecting limited profitability relative to shareholders’ funds. This low profitability metric may deter investors seeking robust returns on equity capital.

Moreover, the stock’s consistent underperformance against the BSE500 index over the past three years, coupled with negative returns in each of the last three annual periods, reinforces concerns about its competitive positioning and growth prospects. The majority of shareholders are non-institutional, which may imply less stable ownership and potentially higher volatility in trading.

Investor Takeaway

In summary, the recent decline in Natraj Proteins Ltd’s share price on 02-Mar is primarily driven by its sustained underperformance relative to market benchmarks, weak long-term sales growth, and modest profitability metrics. While recent quarterly results show operational improvement and attractive valuation ratios, these have not yet translated into positive investor sentiment or price recovery. The stock’s technical weakness, high volatility, and falling investor participation further compound the bearish outlook in the near term.

Investors should weigh the company’s improving profit margins and low valuation against its historical sales decline and consistent benchmark underperformance before considering exposure. Given the current market dynamics and fundamental challenges, caution remains warranted.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →